New treatment for aggressive brain cancer glioblastoma
Official title: MT-125 for the Therapeutic Treatment of Glioblastoma
Funded at Myosin Therapeutics INC. · NIH-11012345 · Data updated 2026-11-12
This study is testing a new treatment called MT-125 for glioblastoma, a tough type of brain cancer, to see if it can help stop the cancer from growing and spreading, with the hope of improving survival for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project start | April 1, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $911,407 |
| NIH project number | 5R42CA278293-03 |
| Project ID | NIH-11012345 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who have not responded adequately to existing treatments.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on developing a new therapeutic agent, MT-125, for treating glioblastoma, a highly aggressive brain cancer. The approach involves using a dual small molecule inhibitor that targets specific molecular motors responsible for tumor growth and invasion. By blocking both the proliferation and invasion of glioblastoma cells, MT-125 aims to improve patient survival rates beyond the current standard of care. The research includes preclinical studies to assess the safety and effectiveness of this new treatment.
Why it matters
Potential benefit: If successful, this research could significantly extend survival and improve quality of life for patients with glioblastoma.
How similar studies have gone: Previous research has shown promise in targeting similar molecular pathways in glioblastoma, but this specific approach with MT-125 is novel.
Where this research is happening
-
Myosin Therapeutics INC.
Jupiter, United States Active
Researchers
- Principal investigator: Rosenfeld, Steven S — Myosin Therapeutics INC.
- Study coordinator: Rosenfeld, Steven S
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.